FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2520-2522 December 13, 2007 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Smith, S. W. PubMed Citation

To the Editor: In her Perspective article on the response of the Food and Drug Administration (FDA) to a report by the Institute of Medicine (IOM) on the U.S. drug-safety system, Weiss Smith (Sept. 6 issue)¹ presents an unfair and uninformed portrayal of the FDA's commitment to drug safety and the many ways the agency is implementing major changes to further improve its drug-safety approach.

The FDA commissioned the IOM report, takes the report very seriously, and developed a comprehensive action plan on the basis of the report. In fact, our January 2007 response garnered praise from the IOM.

Weiss . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.